Vesselon acquires FDA-approved Lipid Microsphere Drug Imagent for therapeutic platform
This article was originally published here
Vesselon will use Imagent to create novel therapeutic complexes in four classes of cancer drugs: cytokines, oncolytic viruses, monoclonal antibodies, and nucleic acid constructs. Vesselon incorporates Imagent into
The post Vesselon acquires FDA-approved Lipid Microsphere Drug Imagent for therapeutic platform appeared first on Pharmaceutical Business review.
Leave a Reply
Want to join the discussion?Feel free to contribute!